The changes of cortical metabolism associated with the clinical response to donepezil therapy in traumatic brain injury.

Abstract:

OBJECTIVES:To determine the effects of treatment with donepezil on cortical metabolism in patients with traumatic brain injury using F-fluorodeoxyglucose positron emission tomography. METHODS:Twenty-six patients with cognitive impairment after traumatic brain injury were enrolled and randomly assigned into the donepezil-treated group and the control group. There was no significant difference between 2 groups in age, sex, education, and postinjury duration. Donepezil 5 mg was administered daily for 3 weeks and then 10 mg/d for 3 weeks to patients in the experimental groups. For both groups, we evaluated cognitive function with Mini-Mental State Examination, Wechsler Memory Test, Boston Naming Test, Colored Progressive Matrices upon initial evaluation and at the 6-week follow-up. An 18F-fluorodeoxyglucose positron emission tomography of the brain was performed before and after 6 weeks of the donepezil-treated group. Effects of donepezil treatment on cortical metabolism were analyzed using Statistical Parametric Mapping software (Institute of Neurology, University College London, UK). RESULTS:There was no significance difference between the 2 groups in initial evaluation of cognitive functions. After 6 weeks, compared with the control group, donepezil-treated group showed enhanced cognitive functions (P < 0.05), and 18F-fluorodeoxyglucose positron emission tomography showed a statistically significant increase in the cerebral cortical metabolism for both of the frontal, parietal, occipital, and temporal cortices (P < 0.01) which are the key role of attention and object naming. CONCLUSIONS:Cholinergic augmentation by donepezil therapy in traumatic brain injury shows a cortical metabolic effect on the both of the frontal, parietal, occipital, and temporal cortices associated with clinical response to treatment.

journal_name

Clin Neuropharmacol

authors

Kim YW,Kim DY,Shin JC,Park CI,Lee JD

doi

10.1097/WNF.0B013E31816F1BC1

subject

Has Abstract

pub_date

2009-03-01 00:00:00

pages

63-8

issue

2

eissn

0362-5664

issn

1537-162X

pii

00002826-200903000-00002

journal_volume

32

pub_type

杂志文章,随机对照试验
  • Remarkable effect of selegiline (L-deprenyl), a selective monoamine oxidase type-B inhibitor, in a patient with severe refractory depression: a case report.

    abstract::A 34-year-old man presented with severe refractory depression. He had failed to respond to various antidepressants, augmentation therapy with lithium carbonate, and modified electroconvulsive therapy. Switching from amoxapine 150 mg/day to selegiline 7.5 mg/day, a selective monoamine oxidase type-B inhibitor, produced...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章

    doi:10.1097/01.wnf.0000171248.89726.2f

    authors: Higuchi H,Kamata M,Sugawara Y,Yoshida K

    更新日期:2005-07-01 00:00:00

  • Metabolic and hormonal effects of dexfenfluramine on stress situations.

    abstract::Chronic treatment of rats with dexfenfluramine decreased the concentrations of circulating corticosterone, fatty acid, glycerol, and triacylglycerol after feeding a test load of fructose. It also decreased the rise in adrenalin in the blood of rats that were anaesthetized with urethane. These effects of dexfenfluramin...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章

    doi:

    authors: Brindley DN

    更新日期:1988-01-01 00:00:00

  • Levetiracetam is not effective for essential tremor.

    abstract:OBJECTIVE:To determine if levetiracetam is efficacious in the treatment of essential tremor. METHODS:Fifteen patients (3 women), aged 35 to 83 years, with essential tremor were studied in a double-blind, placebo-controlled crossover trial of levetiracetam. During the 2 treatment periods, levetiracetam or placebo was t...

    journal_title:Clinical neuropharmacology

    pub_type: 临床试验,杂志文章,多中心研究,随机对照试验

    doi:10.1097/WNF.0b013E31807A32C6

    authors: Elble RJ,Lyons KE,Pahwa R

    更新日期:2007-11-01 00:00:00

  • Reversible monoamine oxidase-A inhibitors in resistant major depression.

    abstract::Monoamine oxidase (MAO) inhibitors (MAOIs) provide effective alternative therapy for those patients with major depression who do not respond to tricyclic antidepressants or such related compounds as the selective serotonin reuptake inhibitors. This article reviews studies on the efficacy of both the classical MAOIs an...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章,评审

    doi:

    authors: Nolen WA,Hoencamp E,Bouvy PF,Haffmans PM

    更新日期:1993-01-01 00:00:00

  • Preclamol and parkinsonian fluctuations.

    abstract::Preclamol, the (-)enantiomer of 3-PPP (= 3(3-hydroxyphenyl)-N-n-propyl piperidine), has a selective dopamine autoreceptor- and postsynaptic mixed agonist-antagonist profile. Its action on patients with disabling on-off parkinsonian fluctuations has been studied and compared with those of placebo and subcutaneous apomo...

    journal_title:Clinical neuropharmacology

    pub_type: 临床试验,杂志文章

    doi:

    authors: Pirtosek Z,Merello M,Carlsson A,Stern G

    更新日期:1993-12-01 00:00:00

  • A review of the antiepileptic drug tiagabine.

    abstract::Tiagabine (TGB), a recently approved antiepileptic drug (AED), has a specific mechanism of action that is unique among AEDs. A potent AED with linear, predictable pharmacokineties, it inhibits gamma-aminobutyric acid (GABA) reuptake into neurons and glia. Tiagabine does not have any clinically relevant effects on hepa...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章,评审

    doi:

    authors: Schachter SC

    更新日期:1999-11-01 00:00:00

  • Falls and Parkinson's disease.

    abstract::One hundred patients with Parkinson's disease (PD) and five patients with progressive supranuclear palsy were questioned about the frequency, circumstances, and consequences of falling. Parkinsonian symptoms were scored using the unified rating scale. Thirty-eight percent of parkinsonian patients fell, and 13% fell mo...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章

    doi:10.1097/00002826-198904000-00003

    authors: Koller WC,Glatt S,Vetere-Overfield B,Hassanein R

    更新日期:1989-04-01 00:00:00

  • The relation between visual hallucinations and visual evoked potential in Parkinson disease.

    abstract:OBJECTIVE:The pathophysiology of hallucinations in Parkinson disease is poorly understood. This study investigated the relation between visual hallucination and visual evoked potentials (VEPs) in Parkinson disease. METHODS:Nineteen patients with Parkinson disease were studied. The authors divided patients into 2 group...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章

    doi:10.1097/01.wnf.0000157066.50948.65

    authors: Matsui H,Udaka F,Tamura A,Oda M,Kubori T,Nishinaka K,Kameyama M

    更新日期:2005-03-01 00:00:00

  • Effects of etoperidone on sympathetic and pituitary-adrenal responses to diverse stressors in humans.

    abstract::The effects of the psychotropic drug etoperidone on the response to laboratory stressors was investigated in a controlled study. Cardiovascular and hormonal (catecholamines, corticotropin, and cortisol) measurements were made in a group of young, healthy volunteers during a cold pressor test (CPT), a mental arithmetic...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章

    doi:10.1097/00002826-199304000-00005

    authors: Costa A,Martignoni E,Blandini F,Petraglia F,Genazzani AR,Nappi G

    更新日期:1993-04-01 00:00:00

  • Is circadian rhythm disruption important in obsessive-compulsive disorder (OCD)? A case of successful augmentation with agomelatine for the treatment of OCD.

    abstract::The main augmentation strategy in the treatment of obsessive-compulsive disorder (OCD) is the addition of low-dose dopamine antagonists, such as risperidone. However, the development of additional pharmacological therapeutics is necessary because some patients remain refractory to these strategies. In the present repo...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章

    doi:10.1097/WNF.0b013e318223421f

    authors: da Rocha FF,Correa H

    更新日期:2011-07-01 00:00:00

  • Fatal Cerebral Edema, Seizures, and Hyponatremia After Trazodone Overdose.

    abstract::Trazodone is a serotonin antagonist and reuptake inhibitor that is widely used for the treatment of depression and insomnia. Fatal overdose is rare and usually occurs when combined with other drugs or alcohol. Only a few lethal cases of pure trazodone overdose have been reported, all attributed to cardiotoxicity. We r...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章

    doi:10.1097/WNF.0000000000000235

    authors: Avila JD

    更新日期:2017-09-01 00:00:00

  • The effect of catechol-O-methyl transferase inhibition by entacapone on the pharmacokinetics and metabolism of levodopa in healthy volunteers.

    abstract::We studied the effect of inhibiting the enzyme catechol-O-methyltransferase (COMT) by a novel COMT inhibitor, entacapone, on the pharmacokinetics and metabolism of levodopa in 12 healthy male volunteers. Single increasing oral doses of entacapone (50-400 mg) were administered concomitantly with a single oral dose of l...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章

    doi:10.1097/00002826-199304000-00007

    authors: Keränen T,Gordin A,Harjola VP,Karlsson M,Korpela K,Pentikäinen PJ,Rita H,Seppälä L,Wikberg T

    更新日期:1993-04-01 00:00:00

  • Acute dystonia during pegylated interferon alpha therapy in a case with chronic hepatitis B infection.

    abstract::Interferon (IFN) is the most widely prescribed drug of choice for chronic hepatitis B infection, which is a common health problem in our country. Therapy with IFN-alpha may be associated with a number of neuropsychiatric symptoms, such as Parkinsonism, akathisia, seizure, and depressive disorders. In this case report,...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章

    doi:10.1097/00002826-200405000-00002

    authors: Atasoy N,Ustundag Y,Konuk N,Atik L

    更新日期:2004-05-01 00:00:00

  • EEG changes induced by oxiracetam on diazepam-medicated volunteers.

    abstract::The present study was carried out in order to verify whether, in benzodiazepine-medicated healthy volunteers, oxiracetam retained the properties already observed after administration in normal volunteers. In a cross-over study, 12 volunteers, medicated the night before with 5 mg diazepam, were i.v. treated with 1 g ox...

    journal_title:Clinical neuropharmacology

    pub_type: 临床试验,杂志文章

    doi:

    authors: Giaquinto S,Nolfe G,Vitali S

    更新日期:1986-01-01 00:00:00

  • Kleptomania after head trauma: two case reports and combination treatment strategies.

    abstract::The purpose of this paper is to add to the growing number of reports about kleptomania occurring in relation to brain injury as well as to present the authors' findings regarding treatment strategies. The authors present two case reports of patients who developed the new onset of kleptomania after closed head trauma. ...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章

    doi:10.1097/01.wnf.0000144042.66342.d3

    authors: Aizer A,Lowengrub K,Dannon PN

    更新日期:2004-09-01 00:00:00

  • Low-dose clozapine for the treatment of Parkinson's disease in a patient with schizophrenia.

    abstract::Clozapine is known to be beneficial for the treatment of dopamine agonist-induced psychotic states in patients with Parkinson's disease (PD). Many reports have suggested that it may also be efficacious for the treatment of parkinsonian tremor. We describe a patient with schizophrenia in whom early-onset PD appeared af...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章

    doi:10.1097/00002826-200103000-00011

    authors: Orr G,Munitz H,Hermesh H

    更新日期:2001-03-01 00:00:00

  • Effects of terguride on anterior pituitary function in parkinsonian patients treated with L-dopa: a double-blind study versus placebo.

    abstract::In a randomized double-blind study, 20 parkinsonian patients (suffering from the disease for 2-18 years), chronically treated with levodopa (500-750 mg/day for 0.5-12 years), received terguride (1 mg b.i.d.) or placebo for 4 weeks. Growth hormone (GH), prolactin (PRL), thyroid-stimulating hormone (TSH), and insulin-li...

    journal_title:Clinical neuropharmacology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1097/00002826-199619010-00006

    authors: Martignoni E,Horowski R,Liuzzi A,Costa A,Dallabonzana D,Cozzi R,Attanasio R,Rainer E,Nappi G

    更新日期:1996-02-01 00:00:00

  • Evaluation of the Short Parkinson's Evaluation Scale: a new friendly scale for the evaluation of Parkinson's disease in clinical drug trials.

    abstract::The extensive use of the Unified Parkinson's Disease Rating Scale (UPDRS) has revealed low interrater reliability in some items and redundancy in others. In view of these shortcomings, we have structured a new scale that includes a zero-to three-point scale for each item in the evaluation of PD. The mental axis includ...

    journal_title:Clinical neuropharmacology

    pub_type: 临床试验,杂志文章

    doi:

    authors: Rabey JM,Bass H,Bonuccelli U,Brooks D,Klotz P,Korczyn AD,Kraus P,Martinez-Martin P,Morrish P,Van Sauten W,Van Hilten B

    更新日期:1997-08-01 00:00:00

  • A study of the cardiopressor effects of lisuride in the treatment of parkinsonism and pathological aging brain.

    abstract::In this study, the hemodynamic and neurochemical effects of lisuride, a dopamine agonist with serotoninergic properties, have been evaluated in de novo parkinsonian patients and in elderly subjects with mild cognitive impairment. Blood pressure (BP), heart rate (HR), and urinary catecholamine (CA) fluctuations through...

    journal_title:Clinical neuropharmacology

    pub_type: 临床试验,杂志文章

    doi:10.1097/00002826-198910000-00005

    authors: Micieli G,Martignoni E,Bono G,Cavallini A,Rossi F,Horowski R,Nappi G

    更新日期:1989-10-01 00:00:00

  • Serotonin receptor subtypes: functional, physiological, and clinical correlates.

    abstract::The effects of 5-HT are varied and widely distributed throughout the human body. At this time, 5-HT research is a field ripe for "plucking." Not only is there a great demand for more selective agonists and antagonists, but there is more than enough work needed in receptor binding studies to keep pharmacologists employ...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章,评审

    doi:

    authors: Bonate PL

    更新日期:1991-02-01 00:00:00

  • Color vision in Parkinson's disease: missing influence of amantadine sulphate.

    abstract::In recent studies, disorders of chromatic and achromatic vision in parkinsonian patients have been demonstrated; these could be partially restored after application of L-Dopa. In this study, the effect of a 3-day infusion therapy with amantadine sulphate on color vision was evaluated in 19 parkinsonian patients by use...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章

    doi:10.1097/00002826-199510000-00009

    authors: Büttner T,Kuhn W,Müller T,Patzold T,Przuntek H

    更新日期:1995-10-01 00:00:00

  • Place of dexfenfluramine in the management of obesity.

    abstract::The treatment of obesity remains a puzzling challenge because long-term maintenance of weight loss--one of the most suitable goals--is rarely achieved with conventional methods. Among the theoretical measures able to maintain a permanent and bearable constraint to obtain the maintenance of weight loss is long-term (li...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章,评审

    doi:

    authors: Guy-Grand BJ

    更新日期:1988-01-01 00:00:00

  • Minimal effective dose and relapse--double-blind trial: haloperidol decanoate vs. placebo.

    abstract::Fifty-six chronic schizophrenic patients were randomized into haloperidol decanoate (HD) or placebo groups for 48 weeks of double-blind treatment. The double-blind trial was preceded by a 15-week single-blind run-in period, during which all patients were treated with 60 mg of HD (approximately corresponding to 3.6 mg ...

    journal_title:Clinical neuropharmacology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:

    authors: Eklund K,Forsman A

    更新日期:1991-01-01 00:00:00

  • Effect of midazolam on memory during fiberoptic gastroscopy under conscious sedation.

    abstract:OBJECTIVE:As the fiberoptic gastroscopy using midazolam is being in widespread use, the exact nature of midazolam on memory should be clarified. We intended to examine whether midazolam causes selective anterograde amnesia and what impact it has on other aspects of memory and general cognitive function. METHODS:We rec...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章

    doi:10.1097/WNF.0000000000000067

    authors: Hong YJ,Jang EH,Hwang J,Roh JH,Kwon M,Lee D,Lee JH

    更新日期:2015-03-01 00:00:00

  • Rotigotine Transdermal Patch Does Not Make Parkinson Disease Patients Sleepy During Daytime.

    abstract:OBJECTIVES:To assess quantitatively the influence of rotigotine transdermal patch on daytime sleepiness, the most common adverse event by non-ergot dopamine agonists (DAs), in Parkinson disease (PD) patients. METHODS:An open-label study enrolled PD patients with unsatisfactory control of motor symptoms. Treatment with...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章

    doi:10.1097/WNF.0000000000000110

    authors: Ohta K,Osada T

    更新日期:2015-11-01 00:00:00

  • Effects of tandospirone on "5-HT1A receptor-associated symptoms" in patients with Machado-Josephe disease: an open-label study.

    abstract:BACKGROUND:We investigated the frequencies of the symptoms such as "ataxia, depression, insomnia, anorexia, and pain," that have been reported to be associated with 5-HT1A receptor, and the effect of tandospirone citrate (tandospirone: 5-HT1A agonist) in patients with Machado-Joseph disease (MJD). METHODS:Ten MJD pati...

    journal_title:Clinical neuropharmacology

    pub_type: 临床试验,杂志文章

    doi:10.1097/00002826-200401000-00005

    authors: Takei A,Fukazawa T,Hamada T,Sohma H,Yabe I,Sasaki H,Tashiro K

    更新日期:2004-01-01 00:00:00

  • Is history of depression a contraindication to treatment with tetrabenazine?

    abstract:OBJECTIVE:To determine whether a history of depression predisposes hyperkinetic patients treated with tetrabenazine (TBZ) to a recurrence or worsening of this symptom. METHODS:We retrospectively reviewed the charts of 518 patients treated with TBZ to determine the frequency of depression and other adverse events. Char...

    journal_title:Clinical neuropharmacology

    pub_type: 临床试验,杂志文章

    doi:10.1097/01.WNF.0000228369.25593.35

    authors: Kenney C,Hunter C,Mejia N,Jankovic J

    更新日期:2006-09-01 00:00:00

  • Pregabalin in zolpidem dependence and withdrawal.

    abstract::Several recent reports attest to zolpidem's strong potential for abuse, dependence, and severe withdrawal symptoms upon its discontinuation. We report, for the first time, on 1 case of heavy zolpidem abuse and dependence with severe withdrawal symptoms twice treated safely and successfully with pregabalin, a newer ant...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章

    doi:10.1097/WNF.0b013e31820a3b5a

    authors: Oulis P,Nakkas G,Masdrakis VG

    更新日期:2011-03-01 00:00:00

  • United States experience and perspectives with trazodone.

    abstract::In the United States, trazodone has shown efficacy comparable with tricyclic antidepressants. Trazodone's side-effect profile, however, is vastly superior to the older drugs. In cases of overdose, trazodone alone has not caused a single death. For depressed patients, starting with 150 mg/day of trazodone, preferably a...

    journal_title:Clinical neuropharmacology

    pub_type: 临床试验,杂志文章,评审

    doi:10.1097/00002826-198901001-00003

    authors: Fabre LF

    更新日期:1989-01-01 00:00:00

  • The emergence of devastating impulse control disorders during dopamine agonist therapy of the restless legs syndrome.

    abstract:INTRODUCTION:The Restless Legs Syndrome is a common sensorimotor disorder, typically amenable to treatment with dopamine agonist therapy. Dopamine agonists have been associated with emergent impulse control disorders (ICDs) when used in patients with Parkinson disease, and ICDs have now been reported in individuals wit...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章

    doi:10.1097/WNF.0b013e31820d6699

    authors: Dang D,Cunnington D,Swieca J

    更新日期:2011-03-01 00:00:00